Wegovy for Cardiovascular Prevention: Evidence, Off-Label Status, and Risk-Benefit Tradeoffs

Is Wegovy approved for cardiovascular prevention?

Yes, for a defined group. The Wegovy injection label, effective June 18, 2026, says that with a reduced-calorie diet and more physical activity it is indicated to reduce the risk of major adverse cardiovascular events (CV death, non-fatal myocardial infarction, non-fatal stroke) in adults with established CV disease and either obesity or overweight [1]. FDA added that indication on March 8, 2024 [3].

Two details matter. The label does not put a number on the weight criterion; it uses the words obesity and overweight [1]. SELECT, the trial behind the approval, enrolled adults aged 45 or older with a BMI of 27 or higher, established CV disease and no diabetes [2]. The CV indication also sits on the same label as the weight-management and MASH indications [1].

The 25 mg daily Wegovy tablet carries the same CV indication in adults [1]. Oral bioavailability is about 1% to 2% versus 89% for the injection, so tablet and injection doses in mg are not interchangeable [1].

What SELECT showed

SELECT was a double-blind, event-driven trial that assigned 17,604 adults with established CV disease and a BMI of 27 or higher, but no diabetes, to semaglutide 2.4 mg weekly or placebo [2]. Mean exposure was 34.2 months and mean follow-up 39.8 months [2].

The primary endpoint of CV death, non-fatal MI or non-fatal stroke occurred in 6.5% on semaglutide and 8.0% on placebo (HR 0.80, 95% CI 0.72 to 0.90) [2]. The event rates differed by 1.5 percentage points over that follow-up [2].

The label breaks the composite into its parts, and they were not equally strong. Fatal or non-fatal MI was 2.8% vs 3.8% (HR 0.72) and all-cause death 4.3% vs 5.2% (HR 0.81). Stroke was HR 0.89 (95% CI 0.72 to 1.11) and CV death 2.5% vs 3.0% (HR 0.85, 95% CI 0.71 to 1.01), and superiority for CV death was not confirmed in the testing hierarchy [1]. The demonstrated result is the three-part composite, not a proven drop in cardiovascular deaths on their own [1][2].

Weight change at week 104 was -9.4% on semaglutide versus -0.9% on placebo [1]. The label states that the exact mechanism of CV risk reduction is not established [1].

What falls outside the approved CV use

Two groups sit outside the CV indication.

Primary prevention. The indication requires established CV disease, and SELECT enrolled only people with pre-existing cardiovascular disease [1][2]. A patient with obesity, high blood pressure and a high calculated risk but no prior event does not meet the CV indication, though they may meet the weight-management indication on the same label [1].

Established CV disease with a BMI under the overweight range. The label requires obesity or overweight, and SELECT required a BMI of 27 or higher [1][2]. A patient with prior stroke and a BMI of 24 is outside the CV indication, and SELECT did not enroll such patients.

Adults with obesity, or with overweight plus a weight-related condition, may still qualify under Wegovy's separate weight-management indication [1].

What the label says to watch for

The Wegovy label lists the warnings below. The CV outcomes trial separately reported serious adverse events and treatment discontinuations [1].

Boxed warning. In rodents semaglutide causes dose-dependent thyroid C-cell tumors at clinically relevant exposures, and whether it does so in humans is unknown. Wegovy is contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1].

Gastrointestinal effects. In the pooled weight-management trials of the 2.4 mg injection (2,116 on Wegovy vs 1,261 on placebo), nausea occurred in 44% vs 16%, diarrhea 30% vs 16%, vomiting 24% vs 6% and constipation 24% vs 11%, and 6.8% vs 3.2% stopped treatment because of adverse reactions [1]. The CV outcomes trial collected only serious events, events leading to discontinuation and events of special interest; there, 16% on semaglutide and 8% on placebo stopped study drug for an adverse event [1].

Pancreatitis and gallbladder disease. The label says to discontinue if pancreatitis is suspected, and confirmed acute pancreatitis occurred in 4 semaglutide-treated adults (0.2 per 100 patient-years) versus 1 on placebo in the trials [1]. Cholelithiasis occurred in 1.6% vs 0.7% and cholecystitis in 0.6% vs 0.2%; the label says gallbladder disease was more frequent than with placebo even after accounting for the degree of weight loss [1].

Kidney injury and heart rate. Acute kidney injury from volume depletion occurred in 0.4 vs 0.2 cases per 100 patient-years (7 vs 4 adults), more often in people with prior renal impairment and during dose titration [1]. Mean heart rate rose 1 to 4 bpm, and a rise of 20 bpm or more occurred in 26% vs 16%; the label says to monitor heart rate at regular intervals [1].

Hypoglycemia is mainly a concern for people also taking insulin or a sulfonylurea. In the weight trial in type 2 diabetes, glucose below 54 mg/dL occurred in 6.2% on Wegovy 2.4 mg versus 2.5% on placebo [1].

Eyes. The current US Wegovy label does not mention NAION [1]. EMA's safety committee concluded in June 2025 that NAION is a very rare side effect of semaglutide (up to 1 in 10,000 users), about one extra case per 10,000 person-years, and advised stopping semaglutide if NAION is confirmed [4].

What happens when treatment stops

The closest data come from a weight trial. In a 327-person extension of STEP 1, participants who had lost 17.3% of body weight on semaglutide regained 11.6 percentage points in the year after stopping, for a net loss of 5.6%, and most cardiometabolic measures moved back toward baseline [5].

Dose used for the cardiovascular indication

Wegovy injection starts at 0.25 mg weekly for 4 weeks, then moves to 0.5 mg, 1 mg and 1.7 mg at 4-week steps, with maintenance from week 17 [1]. For CV risk reduction the label lists 2.4 mg as the recommended dose, with 1.7 mg as an alternative [1]. SELECT used 2.4 mg [2]. The label also allows up to 7.2 mg weekly in adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss; that higher dose was not the dose tested in SELECT [1][2].

For a missed Wegovy injection, the label says the dose may be taken when the next scheduled dose is more than 2 days away [1]. After 2 or more consecutive missed doses, the label directs re-escalating from a lower dose [1].